News
Dupixent Asthma Indication Expanded to Include Younger Patients
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.
Your search for oral corticosteroids returned 8 results
CHEST 2021, News
A New Basis for Predicting Future COPD Exacerbations During the Pandemic
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
Clinical Charts
Antiretroviral Contraindications and Drug Interactions
A list of contraindications and drug interactions for HIV medications.
CHEST 2021, News
Dupilumab Improves Severe Asthma Outcomes, Regardless of Baseline OCS Dose
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
CHEST 2021, News
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
AAO-HNS 2021
Novel Nasal Saline Irrigation System Improves Compliance, Allergic Rhinitis Symptoms
Study authors evaluated the impact on compliance and SNOT-20 scores in patients with allergic rhinitis using a novel sinus nasal rinse device.
AAO-HNS 2021
Corticosteroid Responsiveness Assessed in Patients with Chronic Cough
The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.
News
Saphnelo Approved for Systemic Lupus Erythematosus
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
